Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
13.58
+0.02 (0.15%)
At close: Jul 8, 2026, 4:00 PM EDT
13.70
+0.12 (0.88%)
After-hours: Jul 8, 2026, 6:08 PM EDT
Oculis Holding AG Revenue
Oculis Holding AG had revenue of 209.00K CHF in the quarter ending March 31, 2026, a decrease of -26.67%. This brings the company's revenue in the last twelve months to 1.12M, up 50.07% year-over-year. In the year 2025, Oculis Holding AG had annual revenue of 1.20M with 74.78% growth.
Revenue (ttm)
1.12M CHF
Revenue Growth
+50.07%
P/S Ratio
590.92
Revenue / Employee
18,733 CHF
Employees
60
Market Cap
827.32M USD
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | 513.00K | 74.78% |
| Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
| Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
| Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
| Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
| Dec 31, 2020 | 993.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 204.89M |
| Geron | 196.12M |
| Zevra Therapeutics | 122.29M |
| Theravance Biopharma | 109.78M |
| ARS Pharmaceuticals | 98.99M |
| CytomX Therapeutics | 35.54M |
| Odyssey Therapeutics | 1.06M |
OCS News
- 6 hours ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 6 days ago - Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - GlobeNewsWire
- 27 days ago - Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - GlobeNewsWire
- 4 weeks ago - Oculis Holding AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease - GlobeNewsWire
- 4 weeks ago - Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Oculis Holding AG Slides: Study update presentation - Filings
- 5 weeks ago - Oculis price target lowered to $23 from $42 at JPMorgan - TheFly